IRPC Public Company Limited (IRPC) is set to launch and offer bonds and digital bonds to general investors through ten financial institutions, with projected stable interest rates ranging from 3.70% ...

Bestselling author Veronica Roth, the creator of the Divergent franchise, reflects on the book series' most divisive ...

VIJAYAWADA: BJP MP D Purandeswari raised critical questions in the Lok Sabha on Thursday, pertaining to the progress of ...

Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of clinical data to show that the drug is less likely to be abused.

Tris Pharma has reported positive topline outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol for treating moderate-to-severe acute pain in individuals post-abdominoplasty surgery.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got lots of news coming out of D.C. today ...

Phase 3 trial shows promising pain relief for acute pain patients Tris Pharma, Inc. has announced positive results from its ALLEVIATE-1 phase 3 clinical trial evaluating cebranopadol for treating ...

Top of the morning to you, and a fine one it is, although we confess it is a bit frigid here on the Pharmalot campus. Even the official mascots are spending less time foraging for breakfast.

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...